stockrowAbCellera Biologics Inc.
ABCL Healthcare Biotechnology
AbCellera Biologics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $75.1 million, up 160.6% from fiscal 2024.
- Revenue
- −76.3%
- EPS
- −50.0%
- Free cash flow
- +152.0%
Quarter to June 2026, against a year earlier
Follow ABCL
Alert me
AbCellera Biologics Inc. (ABCL) EBITDA
AbCellera Biologics Inc.'s EBITDA for fiscal 2025 was −$188.3M, compared with −$217.8M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$192.6M. Over the past ten years it has ranged from −$217.8M (fiscal 2024) to $249.6M (fiscal 2022); the current reading is higher than 38% of that period. AbCellera Biologics Inc. ranks 506th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$188.3M | — |
| FY2024 | −$217.8M | — |
| FY2023 | −$206.3M | — |
| FY2022 | $249.6M | 12.61% |
| FY2021 | $221.7M | 37.42% |
| FY2020 | $161.3M | — |
| FY2019 | −$2.3M | — |
| FY2018 | −$23.0K | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$54.0M | — |
| Mar 2026 | −$48.9M | — |
| Dec 2025 | −$20.7M | — |
| Sep 2025 | −$69.0M | — |
| 22 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $96.1M |
| ARQT Arcutis Biotherapeutics, Inc. compare | $36.9M |
| TNGX Tango Therapeutics, Inc. compare | −$137.8M |
| PBLS Parabilis Medicines, Inc. compare | −$172.4M |
| ABCL AbCellera Biologics Inc. | −$192.6M |
| EWTX Edgewise Therapeutics, Inc. compare | −$221.9M |
| IOVA Iovance Biotherapeutics, Inc. compare | −$261.9M |
| RLAY Relay Therapeutics, Inc. compare | −$311.6M |
| XENE Xenon Pharmaceuticals Inc. compare | −$439.2M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on ABCL
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement